The case for a subscription model to tackle AMR: new BCG report published

The case for a subscription model to tackle AMR: new BCG report published

  • 01/04/2022

The recently published report by Boston Consulting Group, prepared together with World Economic Forum, Wellcome Trust, and the Novo Nordisk Foundation, focuses on the threat of AMR, its root causes, and the failure of the market to support sufficient innovation.

Bacteria’s development of resistance to antibiotics, the miracle drug of the 20th century, is a growing threat to global health. The culprits are many, but the result stays the same: bacteria acquire strengths that overpower antibiotic treatments and render them ineffective to useless. A 2019 study attributes 141,000 deaths in high-income countries directly to bacterial AMR. Other studies project that the cumulative global AMR death toll, which currently stands at about 1.27 million, will reach 10 million by 2050, unless significant action is taken. This BCG report focuses on the threat of AMR, its causes, and the failure of the market to take action and spur innovation against AMR. It closely examines the status quo, but also offers a roadmap for taking collective global action to avoid another worldwide public health disaster. In preparing it, BCG worked closely with the World Economic Forum, Wellcome, and the Novo Nordisk Foundation. The report also features leveraged insights from international and country-specific experts, representing the US, the UK, Canada, Japan, France, Germany, and China.

Read the full report: https://www.bcg.com/publications/2022/model-for-tackling-antimicrobial-resistance